---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010507"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:31:47.320456+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028

## Summary
- Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.
- Cash and marketable securities $262M; runway extended into 2028, enabling multiple clinical data readouts.
- Added wholly-owned APOE program to Alzheimer's pipeline, fourth asset in franchise; tau PET data for VY7523 expected H2 2026.
- Neurocrine-partnered FA and GBA1 gene therapy programs expected to enter clinical trials in 2026 after IND submissions in 2025.
- Potential for $2.6B in development milestone payments from 11 partnered programs, including up to $35M from GBA and FA programs.

## SEC filing metadata
- accession: 0001558370-25-010507
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837025010507/0001558370-25-010507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837025010507/vygr-20250806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010507
- JSON: https://secwatch.observer/filing/0001558370-25-010507.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.